Results

BeiGene Ltd.

01/10/2022 | Press release | Distributed by Public on 01/10/2022 06:39

China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Form 8-K